163 related articles for article (PubMed ID: 22774602)
1. [Expressions of E-cadherin and alpha-catenin in benign, malignant and metastatic prostate tumors].
Jiang T; Jiang H; Su XM; Zheng L; Li QL; Zhang ZW; Li XC
Zhonghua Nan Ke Xue; 2012 Jun; 18(6):499-503. PubMed ID: 22774602
[TBL] [Abstract][Full Text] [Related]
2. [Expressions of endothelin-1 in benign prostatic hyperplasia and prostate cancer and their significance].
Zhou WQ; Sun YH; Yin HL; Zhang ZY; Ge JP; Cheng W; Ma HQ; Wei W; Zhou SG; Ma HH; Gao JP
Zhonghua Nan Ke Xue; 2007 Aug; 13(8):685-9. PubMed ID: 17918704
[TBL] [Abstract][Full Text] [Related]
3. [Expressions of the androgen receptor in normal prostate, benign prostatic hyperplasia and prostate cancer].
Zeng R; Liu ZY; Sun YH; Xu CL; Gao X; Jiao L
Zhonghua Nan Ke Xue; 2010 Nov; 16(11):967-72. PubMed ID: 21218636
[TBL] [Abstract][Full Text] [Related]
4. [Expressions of E-cadherin and N-cadherin in prostate cancer and their implications].
Liu Y; Chen XG; Liang CZ
Zhonghua Nan Ke Xue; 2014 Sep; 20(9):781-6. PubMed ID: 25306803
[TBL] [Abstract][Full Text] [Related]
5. [Vinculin and the androgen receptor in prostate cancer: expressions and correlations].
Zhu LY; Zhong KB; Lu SX; He LY
Zhonghua Nan Ke Xue; 2010 Sep; 16(9):794-8. PubMed ID: 21171262
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of the leptin and leptin receptor expressions in prostate tissues.
Hoon Kim J; Lee SY; Myung SC; Kim YS; Kim TH; Kim MK
Asian J Androl; 2008 Nov; 10(6):923-8. PubMed ID: 18958356
[TBL] [Abstract][Full Text] [Related]
7. [P53 expression and its clinical significance in prostatic carcinoma].
Jiang T; Jiang H; Song XS; Li XC; Li QL
Zhonghua Nan Ke Xue; 2005 Jun; 11(6):448-51, 454. PubMed ID: 15999492
[TBL] [Abstract][Full Text] [Related]
8. Epithelial-Mesenchymal Transition Markers β-catenin, Snail, and E-Cadherin do not Predict Disease Free Survival in Prostate Adenocarcinoma: a Prospective Study.
Ipekci T; Ozden F; Unal B; Saygin C; Uzunaslan D; Ates E
Pathol Oncol Res; 2015 Sep; 21(4):1209-16. PubMed ID: 26037169
[TBL] [Abstract][Full Text] [Related]
9. [Expression of PIM-1 in prostate cancer tissue and its relationship with PSA recurrence].
Zhang CT; Xu Y; Luo F; Zhang ZH; Liu RL; Yang K; Ma BJ
Zhonghua Nan Ke Xue; 2012 Apr; 18(4):323-6. PubMed ID: 22574367
[TBL] [Abstract][Full Text] [Related]
10. [Expressions of ERK and p-ERK in advanced prostate cancer].
Han J; Zhang P; Zheng L; Zhang Y; Wang KN; Fan LM; Xie HD; Wang SR; Zhang ZW; Wang QF; Jiang T
Zhonghua Nan Ke Xue; 2017 May; 23(5):406-411. PubMed ID: 29717829
[TBL] [Abstract][Full Text] [Related]
11. Differential immunohistochemical expression of CD44s, E-cadherin and β-catenin among hyperplastic and neoplastic lesions of the prostate gland.
Lazari P; Poulias H; Gakiopoulou H; Thomopoulou GH; Barbatis C; Lazaris AC
Urol Int; 2013; 90(1):109-16. PubMed ID: 23220849
[TBL] [Abstract][Full Text] [Related]
12. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer.
Horvath LG; Henshall SM; Lee CS; Kench JG; Golovsky D; Brenner PC; O'Neill GF; Kooner R; Stricker PD; Grygiel JJ; Sutherland RL
Int J Cancer; 2005 Jan; 113(3):415-22. PubMed ID: 15455387
[TBL] [Abstract][Full Text] [Related]
13. [Expressions of Bcl-xl and caspase-3 in the prostate cancer tissue and their correlation].
Zhonghua Nan Ke Xue; 2016 Apr; 22(4):306-10. PubMed ID: 30088397
[TBL] [Abstract][Full Text] [Related]
14. [Expression of VEGF in prostate cancer and its correlation with ET-1].
Zhou WQ; Yin HL; Zhang ZY; Yi XM; Ge JP; Zhou SG; Cheng W; Wei W; Ma HQ; Ma HH; Gao JP
Zhonghua Nan Ke Xue; 2008 Nov; 14(11):987-92. PubMed ID: 19102498
[TBL] [Abstract][Full Text] [Related]
15. [Correlation of FOXA1 with the malignancy and progression of prostate cancer].
Feng W; Zhang HB; Wang YM; Hu JL
Zhonghua Nan Ke Xue; 2015 May; 21(5):414-9. PubMed ID: 26117938
[TBL] [Abstract][Full Text] [Related]
16. [EZH2 expression in human prostate cancer and its clinicopathologic significance].
Li J; Fan QH; Fan XS; Zhou W; Qiu Y; Qiu L
Zhonghua Nan Ke Xue; 2010 Feb; 16(2):123-8. PubMed ID: 20369694
[TBL] [Abstract][Full Text] [Related]
17. Activation of UPR Signaling Pathway is Associated With the Malignant Progression and Poor Prognosis in Prostate Cancer.
Liu J; Xiao M; Li J; Wang D; He Y; He J; Gao F; Mai L; Li Y; Liang Y; Liu Y; Zhong X
Prostate; 2017 Feb; 77(3):274-281. PubMed ID: 27718273
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of topoisomerase II alpha and Her-2/neu in prostatic carcinoma and benign prostatic hyperplasia.
Hasby EA; Saied EM
J Egypt Natl Canc Inst; 2008 Jun; 20(2):158-67. PubMed ID: 20029472
[TBL] [Abstract][Full Text] [Related]
19. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
Zhang YX; Wang L; Ji PY; Zhao GG; Zhong GP; Wang ZP
Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer antigen-1 as a potential novel marker for prostate cancer.
Liu BQ; Wu YD; Li PH; Wei JX; Zhang T; Liu RL
Asian J Androl; 2007 Nov; 9(6):821-6. PubMed ID: 17968469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
